Gavegnano C - Search Results

1

Repurposing BCL-2 and Jak 1/2 inhibitors: Cure and treatment of HIV-1 and other viral infections.

Reece MD, Song C, Hancock SC, Pereira Ribeiro S, Kulpa DA, Gavegnano C. Reece MD, et al. Among authors: gavegnano c. Front Immunol. 2022 Dec 9;13:1033672. doi: 10.3389/fimmu.2022.1033672. eCollection 2022. Front Immunol. 2022. PMID: 36569952 Free PMC article. Review.

2

Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors.

Gavegnano C, Brehm JH, Dupuy FP, Talla A, Ribeiro SP, Kulpa DA, Cameron C, Santos S, Hurwitz SJ, Marconi VC, Routy JP, Sabbagh L, Schinazi RF, Sékaly RP. Gavegnano C, et al. PLoS Pathog. 2017 Dec 21;13(12):e1006740. doi: 10.1371/journal.ppat.1006740. eCollection 2017 Dec. PLoS Pathog. 2017. PMID: 29267399 Free PMC article.

3

Crossroads of Cancer and HIV-1: Pathways to a Cure for HIV.

Gavegnano C, Savarino A, Owanikoko T, Marconi VC. Gavegnano C, et al. Front Immunol. 2019 Oct 4;10:2267. doi: 10.3389/fimmu.2019.02267. eCollection 2019. Front Immunol. 2019. PMID: 31636630 Free PMC article. Review.

4

The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency.

de Armas LR, Gavegnano C, Pallikkuth S, Rinaldi S, Pan L, Battivelli E, Verdin E, Younis RT, Pahwa R, Williams SL, Schinazi RF, Pahwa S. de Armas LR, et al. Among authors: gavegnano c. Front Immunol. 2021 Aug 31;12:720697. doi: 10.3389/fimmu.2021.720697. eCollection 2021. Front Immunol. 2021. PMID: 34531866 Free PMC article.

5

Targeting Macrophage Dysregulation for Viral Infections: Novel Targets for Immunomodulators.

Reece MD, Taylor RR, Song C, Gavegnano C. Reece MD, et al. Among authors: gavegnano c. Front Immunol. 2021 Nov 1;12:768695. doi: 10.3389/fimmu.2021.768695. eCollection 2021. Front Immunol. 2021. PMID: 34790202 Free PMC article. Review.

6

A Rationale and Approach to the Development of Specific Treatments for HIV Associated Neurocognitive Impairment.

Scanlan A, Zhang Z, Koneru R, Reece M, Gavegnano C, Anderson AM, Tyor W. Scanlan A, et al. Among authors: gavegnano c. Microorganisms. 2022 Nov 12;10(11):2244. doi: 10.3390/microorganisms10112244. Microorganisms. 2022. PMID: 36422314 Free PMC article. Review.

7

Readily available drugs and other interventions to potentially improve the efficacy of immune checkpoint blockade in cancer.

Coleman M, Mascialino SJ, Panjwani A, Edwards E, Sukhatme VV, Gavegnano C, Sukhatme VP. Coleman M, et al. Among authors: gavegnano c. Front Immunol. 2024 Jan 17;14:1281744. doi: 10.3389/fimmu.2023.1281744. eCollection 2023. Front Immunol. 2024. PMID: 38299150 Free PMC article. Review.

8

Honokiol hexafluoro confers reversal of neuropathological markers of HIV infection in a murine SCID model.

Zhang Z, Scanlan A, Koneru R, Morrell CR, Reece MD, Edwards E, Roa S, Gavegnano C, Bimonte-Nelson H, Arbiser J, Tyor W. Zhang Z, et al. Among authors: gavegnano c. Neurotherapeutics. 2024 Mar;21(2):e00329. doi: 10.1016/j.neurot.2024.e00329. Epub 2024 Feb 22. Neurotherapeutics. 2024. PMID: 38388224 Free PMC article.

9

The identification of intact HIV proviral DNA from human cerebrospinal fluid.

Zhang Z, Reece MD, Roa S, Tyor W, Franklin DR, Letendre SL, Marconi VC, Anderson AM, Gavegnano C. Zhang Z, et al. Among authors: gavegnano c. Neurotherapeutics. 2024 May 14:e00373. doi: 10.1016/j.neurot.2024.e00373. Online ahead of print. Neurotherapeutics. 2024. PMID: 38749843 Free article.

10

Antiretroviral therapy in macrophages: implication for HIV eradication.

Gavegnano C, Schinazi RF. Gavegnano C, et al. Antivir Chem Chemother. 2009 Oct 19;20(2):63-78. doi: 10.3851/IMP1374. Antivir Chem Chemother. 2009. PMID: 19843977 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

35 results

Search Page